Monsanto’s Driverless Car: Is CRISPR Gene Editing Driving Seed Consolidation? – KQED
KQED |
Monsanto’s Driverless Car: Is CRISPR Gene Editing Driving Seed Consolidation?
KQED Over the past year, the company has announced several licensing agreements that will allow it to access gene-editing technologies, such as CRISPR/Cas9 and CRISPR–Cpf1 (which is said to be more precise), as well as a tool from Dow AgroScience called … Statement and background on CRISPR patent decision | Broad InstituteBroad Institute UC appeals US patent board decision on CRISPR-Cas9UC Berkeley |
Express.co.uk |
Parkinson’s breakthrough: Scientists one step closer to making a BRAIN out of stem cells
Express.co.uk ‘Cradle of life’ stem cells taken from skin samples were developed into three-dimensional brain-like organisms capable of exchanging signals between each other in a network. The petri dish cells behave in a similar way to the brain cells which produce … Cell cultures in petri dishes open new doors to brain researchNews-Medical.net Scientists Successfully Grow Human Brain Tissue in Petri DishNature World News |
|
Novel CRISPR Diagnostic Developed for Rapid Disease Detection
Genetic Engineering & Biotechnology News Unlike DNA-targeting CRISPR enzymes (such as Cas9 and Cpf1), Cas13a reportedly can remain active after cutting its intended RNA target and may exhibit promiscuous behavior, continuing to cut other nontargeted RNAs in a burst of activity that Zhang lab … |
|
With gene therapy to cure debilitating syndrome ready for clinical trial, the race is on for local children to ‘Out …
SoutholdLOCAL The Rett Syndrome Research Trust has released a Roadmap to a Cure, which outlines a plan to cure Rett and includes a gene therapy trial as its centerpiece. Several studies have completely reversed Rett in animal models and confirm that the same could … |
Targeted Oncology |
Padda Provides Update on the Race to the Frontline With Immunotherapy in Lung Cancer
Targeted Oncology Currently, pembrolizumab (Keytruda) is the only immunotherapy agent approved in the frontline setting for patients with non–small cell lung cancer (NSCLC); however, many other immunotherapy agents and combination regimens are in development that are … |
|
News CRISPR Technique Targeting RNA Described…
Genetic Engineering & Biotechnology News Unlike DNA-targeting CRISPR enzymes (such as Cas9 and Cpf1), Cas13a reportedly can remain active after cutting its intended RNA target and may exhibit promiscuous behavior, continuing to cut other nontargeted RNAs in a burst of activity that Zhang lab … |